Dana-Farber Cancer Institute is running a clinical trial to test drugs called Obinutuzumab and Ibrutinib to treat chronic lymphocytic leukemia. This research study is evaluating a combination of two drugs, ibrutinib and obinutuzumab, as a possible treatment for Chronic Lymphocytic Leukemia (CLL).
The drugs are Obinutuzumab and Ibrutinib.
|Study Type :
||Interventional (Clinical Trial)
|Estimated Enrollment :
||None (Open Label)
||A Phase Ib Study of Ibrutinib in Combination With Obinutuzumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
|Actual Study Start Date :
|Estimated Primary Completion Date :
|Estimated Study Completion Date :
For enrollment please visit www.clinicaltrials.gov.